Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The Minimized Passage Horse: Reconsidering a Symbol for the Cutting edge Period - 2The Main 20 Gaming Control center Ever
- 3The Green Transformation: 5 Feasible Living Practices
- 4Woman, 60, Is Finally Traveling the World Decades After Husband’s Death Held Her Back
- 5Israel faces tough choices over haredi draft exemptions, legal expert warns
- Spanish woman, 25, dies by legal euthanasia in case that drew national spotlight
- 12 times rockets and spacecraft crashed and burned in 2025
- FDA official discusses potential link between COVID-19 vaccines and pediatric deaths
- People with depression can treat themselves at home with new device
- This Week In Space podcast: Episode 189 — Privatizing Orbit
- Dominating Capable Mastercard Utilization: Key Contemplations
- Instructions to Pick the Right Toothpaste for Your Dental Requirements
- Divorce filings, feuds and legal trouble: The 'Mormon Wives' drama keeps piling up
- Rediscovering Imagination in Adulthood: Individual Creative Excursions
